XPro1595 significantly improves neurodegeneration in AD trial
Treatment with XPro1595 for three months caused significant changes in neurodegeneration, synaptic function and neuroinflammation.
List view / Grid view
News
NICE recommends new CAR T-cell therapy to treat mantle cell lymphoma
NICE has recommended that the CAR T-cell therapy Tecartus be given to patients with relapsed or refractory mantle cell lymphoma.
Voclosporin approved by FDA to treat lupus nephritis
The FDA has approved Aurinia Pharmaceuticals' LupkynisTM(voclosporin) for the treatment of lupus nephritis, alongside standard-of-care.
Gavi to make 500,000 doses of Ebola vaccine available for outbreak response
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV∆G-ZEBOV-GP, live, free of charge.
Fire at Serum Institute of India, production site of COVID-19 vaccine
Reports have said five people have been killed in a fire at the Serum Institute of India, where the Oxford-AstraZeneca COVID-19 vaccine is being made.
FDA approves first extended-release injectable, complete regimen for HIV
The approval of Cabenuva (cabotegravir and rilpivirine, injectable formulation) means HIV infected adults could receive once-monthly injections to manage their condition.
President Biden announces intention for US to remain member of WHO
The President of the US, Joe Biden, has written a letter to the UN announcing his intention for the country to remain a part of the WHO.
Computational approach shows antibiotic resistance may spread more easily than expected
A novel algorithm shows that there is a robust network for transferring plasmids between bacteria which may be causing the rapid spread of antibiotic resistance.
Pfizer COVID-19 vaccine effective against B.1.1.7 variant from UK
Research has demonstrated that the Pfizer and BioNTech COVID-19 vaccine can neutralise the B.1.1.7 variant in pre-clinical studies.
Phase II trial to establish whether alisporivir can prevent COVID-19 progression
The trial will primarily assess whether alisporivir (Debio 025) can significantly reduce COVID-19 viral load in hospitalised COVID-19 patients with moderate symptoms.
Clinical microbiology to play key role in COVID-19 response, report says
New research has said that clinical microbiology is critical to understanding COVID-19, with laboratories studying the coronavirus globally.
Johnson & Johnson’s COVID-19 vaccine safely elicits an immune response
An interim analysis of Phase I/II trial data shows 90 percent of 18-55 year olds had a neutralising antibody response that lasts at least two months.
Blood test can identify COVID-19 patients at high risk of life-threatening complications
The rapid blood test could be used to identify hospitalised COVID-19 patients who may benefit from investigational treatments and early interventions.
UK vaccine supply chain workers to be offered COVID-19 jabs
Around 2,000 workers critical to the UK COVID-19 vaccine supply chain will be offered inoculations against the novel coronavirus.
Israel set to be first country to vaccinate entire population against COVID-19
A new report has said that Israel is expected to be the first country in the world to vaccinate its population against COVID-19.
